Safety, efficacy, pharmacokinetics, and mechanisms of novel 10B‐boronophenylalanine combined with a radio‐frequency quadrupole accelerator in boron neutron capture therapy: A preclinical study in head and neck squamous cell carcinoma
Zhaoyuan Zhang, Junyan Li, Minhua Fan, Huafu Ouyang, Qiubo Chu, Huijie Yan, Yannan Zheng, Linxuan Huang, Gui Bao, Zhenting Ma, Shaobo Huang, Lin Li, Xiao Xu, Zhigang Liu · 2026
Read Safety, efficacy, pharmacokinetics, and mechanisms of novel 10B‐boronophenylalanine combined with a radio‐frequency quadrupole accelerator in boron neutron capture therapy: A preclinical study in head and neck squamous cell carcinoma by Zhaoyuan Zhang, Junyan Li, Minhua Fan, Huafu Ouyang, Qiubo Chu, Huijie Yan, Yannan Zheng, Linxuan Huang, Gui Bao, Zhenting Ma, Shaobo Huang, Lin Li, Xiao Xu, Zhigang Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13399582.txt.
Description
Zhaoyuan Zhang and co-authors tested a new boron drug and accelerator pairing for boron neutron capture therapy in head and neck cancer models, reporting in 2026. The treatment works in two steps: a boron-carrying compound concentrates in tumor cells, then a neutron beam triggers tiny, cell-sized destructive reactions inside them. The team paired a novel boronophenylalanine compound with a radio-frequency quadrupole accelerator neutron source and ran a full preclinical workup.
The compound reached tumors quickly and selectively, settling at a tumor-to-blood ratio of about 3.5 in the reported imaging. Tumor shrinkage grew with dose. Inside treated cells, the therapy provoked a hypoxia-like stress response. Reactive oxygen species piled up and DNA suffered double-strand breaks. Two signaling axes, HIF-1 alpha and NF-kappa-B, switched on along the road to cell death. The authors say the system's safety and mechanism suit translation toward human trials.
Catalog record
| CREATOR | Zhaoyuan Zhang, Junyan Li, Minhua Fan, Huafu Ouyang, Qiubo Chu, Huijie Yan, Yannan Zheng, Linxuan Huang, Gui Bao, Zhenting Ma, Shaobo Huang, Lin Li, Xiao Xu, Zhigang Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36570 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |